Kelly Knee joined Pfizer in 2012. After receiving her Ph.D. in 2007 from Wesleyan University, she went on to do a postdoctoral research fellowship at the MIT, Cambridge from 2007-2011. Later, she worked as a Strategic Consultant in Global Blood Therapeutics from 2011-2012. Kelly Knee now working as a Principal Scientist Rare Disease Research Unit at Pfizer.
Kelly Knee has broad interests on Haemophilic Diseases. Her major focus of research on sickle cell diseases.